Navigation Links
NIU Seeks OK for New Proton Cancer Treatment and Research Center

President Peters declares spirit of hope and focus on mission

CHICAGO, Feb. 25 /PRNewswire/ -- Northern Illinois University today named Northwestern Medical Faculty Foundation as its expected provider of clinical services for a new $160 million proton therapy cancer treatment and research center to be built in the DuPage National Technology Park about 35 miles west of Chicago.

The announcement came as Northern Illinois University President John Peters presented formal testimony before the Illinois Health Facilities Planning Board in Chicago seeking the final go ahead for the project.

"NIU is deeply saddened by recent events and yet so very proud of the way our student body, faculty and administrative team responded during this difficult time and came together with hope for the future," Dr. Peters said. "We are here today in that spirit of hope and with constant focus on our mission. We are pleased our application for the proton treatment center received an entirely positive report from the Illinois Department of Public Health. We look forward to final approval by the Planning Board so we can begin construction of this facility that will stand in testament to our mission as a world class educational, research and now, cancer treatment center."

NIU Board of Trustees Chair Cherilyn Murer hailed the collaboration with Northwestern saying that NIU's expertise in advanced accelerator physics and engineering coupled with the world class cancer treatment experience of doctors from the Northwestern Medical Faculty Foundation in Chicago would make NIU's proton treatment center the best in the world.

"Our anticipated collaboration with Northwestern Medical Faculty Foundation speaks to the high caliber of our endeavor," Murer said. "While patient focus will be our primary objective, the incredible by-products we will offer through education and research in the form of medical, scientific and technology protocols will work to advance the human condition across the globe. Ours will be far more than a community proton center to treat cancer. We envision the NIU facility as a regional and even national resource complimented through NIU's work with Fermilab and Argonne National Laboratories, both world leaders in accelerator physics, neutron and proton therapies."

Under the expected collaborative agreement between NIU and Northwestern Medical Faculty Foundation, physicians who are full-time faculty members or researchers at the Feinberg School of Medicine and are on the attending physician staff at Northwestern Memorial Hospital will deliver clinical and related services at the new state-of-the-art cancer treatment center. Officials expect the agreement to be finalized within three months.

The Illinois Health Facilities Planning Board staff report issued earlier this month found the NIU application for a certificate of exemption (COE) complete and in full compliance with requirements.

"We have done all that has been asked of us and much more. We are ready and eager to begin our new endeavor and we look forward to fulfilling our mission of outreach and service to all the people of Illinois," said John Lewis, project director and associate vice president at NIU.

Currently there are only five proton therapy centers in the country. Patients often travel hundreds or thousands of miles to receive this form of specialized cancer treatment. Proton therapy is an advanced and highly effective form of radiation treatment utilizing proton beams created at extremely high speeds using a particle accelerator that is housed in a structure the size of a football field. It is non-invasive, extremely precise and painless. Unlike conventional radiation therapy, proton beam treatments destroy only the tumor leaving good tissues unaffected. It has been proven to be especially effective in treating prostate and head and neck cancers as well as pediatric cancer, where preservation of organs, systems and tissue during critical formative years is of utmost importance. The male African American population is at particular risk for prostate cancer and suffers a higher incidence of the disease than other groups.

In keeping with its mission of public service, NIU has also negotiated a payment schedule with the Illinois Department of Public Aid for treating Medicaid patients and expects to offer its services to a full spectrum of applicants.

The facility will be known as the Northern Illinois Proton Treatment and Research Center, LLC.

SOURCE Northern Illinois University
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. West Michigan Science & Technology Initiative Seeks Exhibitors for Annual Life Science Showcase
2. GBC Seeks Nominations for Regions Third Annual Bioscience Awards
3. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
4. Murray Leads Delegation in Securing $2.1 Million for Proton Therapy Center
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
7. Quest Diagnostics to Develop Blood Test to Aid in the Detection of Colorectal Cancer
8. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
9. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
10. More than $6 Million Raised During Two-Day Event to Support Research and Treatment for Childhood Cancer and Other Catastrophic Diseases
11. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
Post Your Comments:
(Date:11/24/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that ... and invited investors to participate via webcast. ... 1, 2015 at 11.00 a.m. Eastern Time --> ... 1, 2015 at 11.00 a.m. Eastern Time --> ... NY      Tuesday, December 1, 2015 at 11.00 ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for Pharmaceutical ... the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took ... hosted the largest number of attendees in more than a decade. , ...
(Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
Breaking Biology Technology:
(Date:11/19/2015)... MOUNTAIN VIEW, Calif. , Nov. 19, 2015 /PRNewswire/ ... authentication market, Frost & Sullivan recognizes BIO-key with the ... Strategy Leadership. Each year, Frost & Sullivan presents this ... comprehensive product line catering to the needs of the ... which the product line meets and expands on customer ...
(Date:11/17/2015)... 2015 Paris from 17 ... Paris from 17 th until 19 ... innovation leader, has invented the first combined scanner in the ... same scanning surface. Until now two different scanners were required: one ... capture both on the same surface. This innovation is ...
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
Breaking Biology News(10 mins):